Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
US biotech Cidara Therapeutics and the UK’s Mundipharma today announced positive top-line data from the pivotal ReSTORE Phase III clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. 14 December 2021
Pharmaceutical
After a few of days speculation and rumors, Australia-headquartered biotech CSL Limited today confirmed it has entered into a definitive agreement to acquire Switzerland-based Vifor Pharma, a specialty pharmaceutical company with leadership in iron deficiency, nephrology and cardio-renal therapies. 14 December 2021
Biotechnology
UK clinical stage biopharma company Vaccitech yesterday announced that it has acquired USA-based Avidea Technologies. 14 December 2021
Biotechnology
Shares of Chinese drug developer Brii Biosciences fell yesterday despite the firm announcing new in vitro pseudoviris neutralization data demonstrating that its amubarvimab/romlusevimab combination therapy (previously referred to as combination BRII-196/BRII-198) retains activity against the new Omicron SARS-CoV-2 variant (B.1.1.529). 14 December 2021
Biotechnology
Shares of Foghorn Therapeutics were up nearly 43% at $17.18 (having risen as high as $18.15) by mid-morning, after the US biotech revealed a lucrative research collaboration with Eli Lilly’s Loxo Oncology unit for the use of its proprietary Gene Traffic Control platform. 13 December 2021
Biotechnology
Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval for the use of regdanvimab (trade named Regkirona) in adult patients with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. 10 December 2021
Biotechnology
US biotech Intercept Pharmaceuticals shares closed down nearly 15% at $14.56 yesterday, after it announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to non-alcoholic steatohepatitis (NASH). 10 December 2021
Biotechnology
Dutch gene therapy company uniQure and CSL Behring, part of Australia’s CSL Limited, have announced encouraging results on etranacogene dezaparvovec. 9 December 2021
Pharmaceutical
The US Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for Zynrelef (bupivacaine and meloxicam) extended-release solution to significantly expand the indication, which was submitted by US drugmaker Heron Therapeutics, whose shares were up 6.2% at $9.05 by mid-morning. 9 December 2021
Biotechnology
The US Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee came up with a negative opinion following its meeting yesterday on bardoxolone methyl for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome. 9 December 2021
Biotechnology
China’s National Medical Products Administration (NMPA) has granted approval of Sino-American firm Brii Biosciences’ monoclonal neutralizing antibody (MAb) therapy, the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination). 9 December 2021
Biotechnology
Czech immuno-oncology (I-O) specialist SOTIO Biotech, part of the investment company PPF Group, has entered into a clinical trial collaboration and supply agreement with Merck & Co, the US pharma giant known as MSD outside North America. 8 December 2021
Pharmaceutical
The boards of directors of UK-headquartered pharma services and products company Clinigen Group and of Triley Bidco Limited (Bidco) have agreed the terms of a recommended all-cash acquisition of Clinigen by Bidco, a newly-incorporated company indirectly owned by the Triton Funds, a European private equity investment firm, whereby Bidco will acquire the entire issued and to be issued ordinary share capital of Clinigen. 8 December 2021
Pharmaceutical
US RNA-targeted drug developer Ionis Pharmaceuticals entered into a development and commercialization deal with the UKs AstraZeneca for eplontersen, formerly known as IONIS-TTR-LRX, sending the US firm's shares 7% higher to $29.44 by late morning today. 7 December 2021
Pharmaceutical
Shares of Acadia Pharmaceuticals closed up more than 21% at $23.07 yesterday, after the US drugmaker released better than expected clinical results for its trofinetide. 7 December 2021
Pharmaceutical
Despite hitting its primary endpoint, results from the Phase III PEACE trial were not strong enough for investors, denting stock in Texan biotech Aeglea BioTherapeutics on Monday. 7 December 2021
Biotechnology
UK clinical-stage biotech Redx Pharm edged up 5% to 62.80 pence this morning, as it announced a partnership with Caris Life Sciences, a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. 6 December 2021
Biotechnology
Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO). 6 December 2021
Biotechnology
The China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). 3 December 2021
Pharmaceutical
Sino-American cancer drug developed BeyondSpring Pharmaceuticals (Nasdaq: BYSI) saw its shares plummet more than 60% yesterday, and a further 5.7% to $4.65 pre-market today, after it revealed receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). 2 December 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze